Biomea Fusion To Start Early-Stage Leukemia Setting Trial With BMF-219

by Vandana Singh, Benzinga Editor

September 16, 2021 3:49 PM | 1 min read | Make a Comment

The FDA has signed off Biomea Fusion Inc's BMEA Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor.
The trial will include adult patients with relapsed or refractory acute leukemia, including those with an MLL/KM2TA gene rearrangement or NPM1 mutation.
The trial will assess the safety, pharmacokinetics (PK), and pharmacodynamic (PD) profile in adult patients.
Related content: Benzinga's Full FDA Calendar.
Price Action: BMEA shares were up 5.64% at $11.23 before the trading was halted during the market session on the last check Thursday.

Posted In: Biotech News Health Care Small Cap FDA Movers Trading Ideas General Briefs leukemia Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.